Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1⁺ CD8⁺ T cells in HCC via blocking VEGFR2.

ABSTRACT: Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1⁺ CD8⁺ T cells in HCC microenvironment have not been systematically studied. Here, we established an orthotopic hepa1-6 mouse model treated with lenvatinib to investigate CD8⁺ T cells' role in the tumor and spleen. We found an increasing proportion of TCF-1⁺ in PD1⁺ CD8⁺ T cells and proliferation of PD1⁺ CD8⁺ T cells after lenvatinib treatment. Meanwhile, lenvatinib treatment upregulated the expression of granzyme B on PD1⁺ CD8⁺ T cells both in vitro and in vivo. Lenvatinib activated the endoge

SUBMITTER: Mei Z 

PROVIDER: S-EPMC10067412 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature